歌禮製藥-B(01672.HK)在美國皮膚病學會年會上展示治療痤瘡藥物研究結果
歌禮製藥-B(01672.HK)公布,在美國聖疊戈舉行的2024年美國皮膚病學會(AAD)年會上以壁報形式展示同類首創脂肪酸合成(酉每)(FASN)抑制劑ASC40治療痤瘡的II期研究最終結果。
結果顯示,在所有劑量下,上述療效指標從第2周到第12周普遍有所改善。每日一次50毫克顯示出最佳療效。根據該2期試驗的療效和安全性數據,每日一次50毫克ASC40,為期12周治療的3期臨床試驗已啟動。公司已從Sagimet Biosciences Inc.獲得ASC40在大中華區的開發、生產和商業化獨家權益。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.